Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-05
2011-07-05
Jarrell, Noble (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S274000, C544S008000, C544S316000
Reexamination Certificate
active
07973035
ABSTRACT:
The invention is directed to compounds of Formula I:wherein Z, X, J, R2and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
REFERENCES:
patent: 6100254 (2000-08-01), Budde et al.
patent: 6235746 (2001-05-01), Davis et al.
patent: 6346625 (2002-02-01), Karabelas et al.
patent: 6383790 (2002-05-01), Shokat
patent: 7429603 (2008-09-01), Player et al.
patent: 7645755 (2010-01-01), Illig et al.
patent: 7662837 (2010-02-01), Illig et al.
patent: 2005/0113566 (2005-05-01), Player et al.
patent: 2006/0040995 (2006-02-01), Bacque et al.
patent: 2006/0148812 (2006-07-01), Illig et al.
patent: 2006/0258666 (2006-11-01), Player et al.
patent: 2007/0249593 (2007-10-01), Illig et al.
patent: 2007/0249608 (2007-10-01), Illig et al.
patent: 2007/0249649 (2007-10-01), Illig et al.
patent: 2007/0249680 (2007-10-01), Illig et al.
patent: 2007/0249685 (2007-10-01), Illig et al.
patent: WO 00/27820 (2000-05-01), None
patent: WO 01/47897 (2001-07-01), None
patent: WO 01/49667 (2001-07-01), None
patent: WO 02/068406 (2002-09-01), None
patent: WO 2004/022525 (2004-03-01), None
patent: WO 2004/096795 (2004-11-01), None
patent: WO 2006/047277 (2006-05-01), None
patent: WO 2006/047504 (2006-05-01), None
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Byrn et al., Solid-State Chemistry of Drugs, Second Edition, 1999, pp. 233-247.
Guillory (in Brittain ed.) Polymorphism, etc., NY: Marcel Dekker, Inc., 1999, 1-2, 183-226.
Ballentine Shelley K.
Chen Jinsheng
Desjarlais Renee Louise
Illig Carl R.
Meegalla Sanath K.
Janssen Pharmaceutica N.V.
Jarrell Noble
LandOfFree
Inhibitors of C-FMS kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of C-FMS kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of C-FMS kinase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731401